News | August 12, 2021
Hester Biosciences posts PAT of Rs 11.01 cr in Q1FY22
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
Demand normalisation post the second wave contributed to the steady growth
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
The profits were bolstered by the Boehringer Ingelheim MEK program income
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Subscribe To Our Newsletter & Stay Updated
